As autumn begins, concerns about seasonal influenza have intensified in workplaces, industrial projects and organizations. This year's anxiety coincided with a reported global supply delay, encouraging rumors, inflated multimillion-toman prices and misleading social-media sales. Drawing on Ministry of Health and Food and Drug Organization assessments, HSE management warned about unauthenticated vaccines and their biological risks.
The source traces the issue to a global scientific reformulation. WHO reviewed quadrivalent vaccines after monitoring seasonal strains and removed one strain from recommendations. The report says this delayed international production and affected supply from Europe to the Middle East. Iranian importers, who had planned orders since the previous winter, faced delayed European deliveries and greater European demand. Combined with a reported halt in domestic recombinant-vaccine production following weak demand in earlier years, the gap created opportunities for intermediaries and online profiteers.
The report frames the concern as more than excessive pricing. It describes vaccines as temperature-sensitive biological products requiring an uninterrupted cold chain, stated as 2–8°C. Unauthorized storage or passenger-courier transport without continuous temperature logging can damage active components. The original article warns that compromised products may fail to provide protection and may create serious adverse-reaction risks, including anaphylaxis and other complications, classifying the exposure as potentially catastrophic in an occupational-health risk matrix.
According to the regulatory statements cited, more than 700,000 doses of authorized French, Russian and Chinese vaccines had arrived and distribution had begun, with further phased clearance bringing planned capacity to 2.8 million doses. More than one million doses were allocated free to high-risk people, those with underlying conditions, healthcare staff and vulnerable groups. Authorized pharmacy supplies were described as regulated and priced below two million tomans, unlike inflated online offers.
HSE management urged employees, executives and supervisors to avoid risking family health on social-media advertising and smuggled products. The source identifies the TTAC health-product tracking system as the authorized route for authenticity verification. Prioritizing high-risk workers, obtaining vaccines through official distribution and following basic personal hygiene were presented as the most reliable measures for navigating seasonal illness and reducing lost workdays.
Source links: www.who.int
Original publication date (Solar Hijri): 1405/07/06
Author: Dibagostaran Sanat